ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer.

Related Keywords

Littleton ,Colorado ,United States ,Manojkumar Bupathi ,Mountain Cancer Centers In Littleton ,Institutional Perspectives ,Rocky Mountain Cancer Centers ,Enfortumab Vedotin ,Pembrolizumab ,Urothelial Carcinoma ,Targeted Therapy ,Ev 302 Trial ,Icra Trial ,